Women in the United States use hormonal contraceptives more than any other nation in the world. Doctors and patients in other countries report a hesitance to prescribe hormonal contraceptives for off-label use (to improve the skin, or regulate the cycle) where most pharmaceutical advertisements in the US celebrate exactly those uses.
Why do women in the US use hormonal contraceptives more frequently? How did you and your doctor decide that this prescription was right for you?
If you live in or near Champaign-Urbana, we would like to have you come participate in a focus group on exactly this topic! We would like to validate a survey that will be used online, but also get freeform responses from real women about their real experiences.
Please email us to participate! We can answer any questions you may have. You must be:
- Over eighteen years old
- Have been prescribed hormonal contraceptives at least once
- Filling out an eligibility survey and indicating your time preference for the focus group (5 minutes)
- Attending a focus group, where you will fill out a survey and discuss your broader experiences with hormonal contraceptives (90 minutes)
We will provide you with some tasty snacks during the focus group. So far we have found that participants have really loved being a part of this, because it’s given them a chance to reflect on their own contraceptive choices. Join us! Email us today! You will be helping us put together a comprehensive research program to understand why US women take hormonal contraceptives far more than women from other developed countries.
IRB approval for this message: #12269, amendment 02/22/2010
When I was in college, my favorite hangout was the basement of the Harvard Book Store, where they had the used books and cheap remainders (they were also across the street from my freshman dorm, Wigglesworth, and yes, that is a most excellent name). I worked my way through several sci-fi and fantasy series, and got nearly all my Women’s Studies books, because of that one lovely room.
One night in my freshman year I was browsing the philosophy section with a new boyfriend, a person with whom I often felt inferior and less-educated. I saw an author name on the spine of an old hardcover and, hoping to impress the boyfriend, pointed it out. “Hobbes Machiavelli, I’ve read stuff by him,” I said. I arched my eyebrows with what I hoped was an air of intelligence.
The boyfriend, and a nearby witness, both turned towards me. “Hobbes and Machiavelli are two different people,” he said slowly.
As a blush crept up my face, I realized several things: the excerpt of “The Prince” I had barely skimmed in high school was by Niccolo Machiavelli, Hobbes was a totally different dude, and my boyfriend thought I was a posturing idiot.
It’s a good idea to know what you’re talking about before opening your mouth.
* * *
These days, if I don’t know the answer to something, I don’t try to fake it. Recently, a Twitter follower suggested I write on this New Scientist story and the empirical article upon which it was reporting on brain activity, hormones and Premenstrual Dysphoric Disorder. As I am not an expert on issues of the brain, rather than try to be I enlisted brilliant neuroscientist Scicurious to do tag-team blog posts where we could each cover the material where we had expertise. I had a few thoughts about the way the New Scientist article author framed the study, and about the hormone analyses. So I’ll talk about that, and Sci will cover BRAINZ in this post.
What is this study about?
Rapkin et al (2011) seek to understand why a minority of women experience Premenstrual Dysphoric Disorder (PMDD), a suite of premenstrual behaviors that include severe and debilitating irritability, depression and anxiety. They used PET scans to look at brain stuff (cue Scicurious) and also looked at hormone concentrations to see if the reproductive hormones that decline in the premenstrual phase had anything to do with it. They found no difference in hormone concentrations between control and PMDD women, but did find variation in cerebellar activity by menstrual phase. You need to read Scicurious’s take on this, because she provides important background and context to the study of the cerebellum for mood.
The New Scientist piece makes a lot of the potential effect of progesterone on GABA receptors in the brain, but as far as I can tell the article itself does not measure GABA receptors. Progesterone, allopregnanolone and GABA are all interrelated and important chemicals when it comes to mood (Concas et al 1998), but like I said, since the study didn’t actually look at GABA, I’m not going there. Sci has also made some important points about this issue, and on what the study authors found (which is admittedly cool) with what they discuss around GABA (which might be a wee bit of a stretch).
Nits to pick with New Scientist
Zukerman, the author of the New Scientist piece, begins her piece, entitled “Why women get anxious at ‘that time of the month’” with this:
“Is it that time of the month? These are the words no man should ever utter. How about this for a diplomatic alternative: “Are your GABA receptors playing up?”
You may be spot on. It seems that these brain cells are to blame for some women’s monthly mood swings.
Many women feel a little irritable before menstruating, but up to 8 per cent suffer extreme symptoms, including anxiety, depression and fatigue.”
There are a few things that trouble me about this. First, without citing any actual incidence of this symptom, the author claims that many women suffer from irritability before their period. This just perpetuates the idea that irritability is a common premenstrual trait, when the premenstrual phase is an incredibly variable period. This is despite the fact that at most only eight percent of women actually get these symptoms to the point that they are debilitating (the two studies the study authors cite give a 5% and 8% incidence, so 8% may be high).
From a public health or science research perspective, eight percent of reproductively aged women is a pretty significant quantity. I absolutely want more research to be done on PMDD and, full disclosure, I’m running some pilot studies to work on it in the future myself. However, these results don’t necessarily translate to women who may just get a little irritable or experience other mild behavioral symptoms before their period.
And that is why both the title and the “Is it that time of the month” joke at the start of the story were misleading. Besides its obvious sexism, where any female behavior that deviates from the pleasing and passive risks eliciting that question, the link here in the mind of a popular reader is that women’s behavior is governed by hormone and brain interactions more generally than the paper actually implies.
So, to reiterate: PMDD impacts maybe eight percent of reproductively aged women (notice that I keep specifically referencing “reproductively-aged women,” which further shrinks the pool of women down to those between menarche and menopause). This is nothing to sneeze at. But this isn’t everyone.
In order to see if there were differences in hormone concentrations between normal and PMDD women, Rapkin et al (2011) took blood on the days of the PET scans: this translated into one follicular phase (first half of the cycle, between menses and ovulation) and one late luteal phase collection (the week or so before the next menses). They found no difference in the mean concentrations of estradiol and progesterone between the two groups, at either time period.
|Table 1 from Rapkin et al (2011). None of these differences between groups are significant according to the authors, but they didn’t report p-values anywhere I could find.|
There are several problems with this. First, the sample size is tiny. I have certainly been known to run analyses with fewer subjects, but the way I and other folks who do hormone work get around this is to sample each individual many more times. When collecting hormone information on reproductively-aged women, for instance, you want to collect a minimum of one menstrual cycle’s worth of data… every single day.
My advisor raised me right, and so I did a power analysis of the data the study authors provided. A power analysis is a way to determine the statistical power of a test. You can do it beforehand to determine an appropriate sample size for your experiment, or afterwards if you didn’t find something statistically significant and don’t know if your analysis was effective. When there are small but important differences between two groups, but the sample size is also small, your statistical test can be insignificant and thus miss that important difference.
Let’s take the hormone and time period that should be the most meaningful: progesterone in the late luteal phase. PMDD women had 5.50 ± 5.27 ng/mL, and control women had 6.76 ± 7.53 ng/mL. If we say that the smallest difference between these two groups that would be interesting is around 6 ng/mL (just splitting the difference between the two standard deviations, but this is pretty generous), then according to my calculations this test only has a power of about 60%. Therefore, 40% of the time a test with a sample size this small wouldn’t catch a potentially important difference between the groups. To put it into more perspective, the standard is to have a power of at least 80%.
What’s blood got to do with it?
|On Fertile Ground, by Peter T. Ellison. Go to the Amazon page to embiggen the image and you’ll see the plastic tube one of the women is holding to collect spit.|
Most people with a clinical background or doing a more clinical collaboration seem to be needle-happy. That is, when they want to measure hormones, they take it out of your arm rather than from the many other places you can get it: blood spots (using a little lancet on your finger), saliva, urine, and feces. This will some day be a blog post in its own right.
Here is the short answer: saliva is very often better than venous blood. Hormones are secreted from their organs in a pulsatile way, meaning they are released in short bursts, which leads to measurements going up and down quickly. Since they circulate in the blood, serum measurements of hormones are likely to pick up this noise. This is yet another reason why only two samples for each of the twenty four subjects is troubling. There are other reasons, related to what version of the hormone you are measuring when getting it from blood, spit or elsewhere, the higher compliance and greater frequency of sampling you can do with saliva, and the fact that you don’t have to stick your subjects or increase their risk of infection.
The only studies looking at variation in hormones across the cycle in menstrually-related mood disorders use blood (Bloch et al 1998, Rubinow et al 1988). The Bloch et al 1998 measures 10 women with PMS and 10 controls using serum every day for a cycle (hooray, every day!) but they measure testosterone, cortisol, and other hormones not comparable to this study. Plus, they are looking at women with PMS, not PMDD, which is a much more broadly-defined syndrome. It would be harder to find a difference between these two groups than controls and women with PMDD.
The Rubinow et al 1988 is old enough that I can’t get it online, the abstract says nothing about how frequently the hormones are measured or the number of women in the study, and I don’t know how strictly they define menstrual disorders (again, as opposed to the rather strictly-defined PMDD).
Variation is the spice of life
My last issue with the hormones is with the two windows during which they measured them. Women were measured in their follicular phase anywhere from 8-12 days into their cycle for the first measurement; then the late luteal phase measurement was 10-14 days after a measured LH surge (which occurs around midcycle).
Here is the kind of variation I see when I measure women’s hormone concentrations every day. What you’re looking at is salivary estradiol (pmol/L) measured daily in over twenty Polish women, aligned by midcycle drop date. The first graph is all the women together, the second is the average and standard deviation.
|Individual Polish women’s estradiol concentrations.|
|Average Polish women’s estradiol concentrations.|
Here is salivary progesterone from the same population, aligned by the end of the cycle. Again, the first graph is everyone individually, the second is average and standard deviation.
|Individual Polish women’s progesterone concentrations.|
|Average Polish women’s progesterone concentrations.|
A few important things to note: this isn’t the same way the study authors aligned their data (though the way I have shown it here is more physiologically meaningful) and the units are different. However, if you look at about the times when the study authors were taking their measurements – mid to late follicular phase and late luteal phase – you see a TON of variation between those days, both within and between women. This is why a single measurement in that general window is, in essence, of no use. You have way too much noise in a single measurement to be able to begin to say anything about differences between groups.
PMDD is very likely related to hormone concentrations – if not in their average values between groups, then in how those hormones differentially impact brain functioning (the brain sensitivity stuff Sci discusses so well). But we won’t know these potential differences if we don’t gather the hormone data correctly. Just because brain scans are cool — and really, they are and I applaud the study authors for doing stuff that I simply cannot do and finding interesting results — doesn’t mean you can give the hormones the short shrift.
Bloch M, Schmidt PJ, Su TP, Tobin MB, & Rubinow DR (1998). Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls. Biological psychiatry, 43 (12), 897-903 PMID: 9627744
Concas A, Mostallino MC, Porcu P, Follesa P, Barbaccia ML, Trabucchi M, Purdy RH, Grisenti P, & Biggio G (1998). Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proceedings of the National Academy of Sciences of the United States of America, 95 (22), 13284-9 PMID: 9789080
Rapkin AJ, Berman SM, Mandelkern MA, Silverman DH, Morgan M, & London ED (2011). Neuroimaging evidence of cerebellar involvement in premenstrual dysphoric disorder. Biological psychiatry, 69 (4), 374-80 PMID: 21092938
Rubinow DR, Hoban MC, Grover GN, Galloway DS, Roy-Byrne P, Andersen R, & Merriam GR (1988). Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. American journal of obstetrics and gynecology, 158 (1), 5-11 PMID: 2962499
Agora is the women in science community developed by the L’Oreal Foundation. Recently I was asked to write a piece for them that talks about my work. You can find it here.
A snippet to entice you:
“The reason it’s so important to me that I be that activist scientist – someone whose work is informed by an understanding of the biases inherent in the process of science, and who promotes a deeper understanding of science to the general public – is that women’s health is something that many non-experts opine about, providing sometimes dangerous disinformation.”
I have been quite the fancypants lately. In addition to the flood of new traffic from Science Online 2011, and in particular my post on the women scienceblogging panel, folks have been heading here to talk about broader issues of underrepresentation and racism, and, of course, iron-deficiency and the ladybusiness.
Then, because of a happy accident and the fact that Laura Weisskopf Bleill of Chambanamoms.com wanted to help me promote some focus groups I am running for a study on doctor-patient relationships around hormonal contraceptives,* I became a Chambana Mom to Know. At the same time I was recruited by the ever-clever John Hawks to do a bloggingheads.tv diavlog where we discuss women in science, blogging in academia, my fieldwork, the ladybusiness, #aaafail, and lots of other stuff.
I am feeling quite overwhelmed by the fact that I have a lot of new readers, and this is no longer the intimate space it once was (usually when I write, I imagine myself to be talking to a group of female friends while we sit on the couch and hang out – it now feels like giving a seminar to a medium-sized room full of people, where we are somehow still able to manage cool sidebar conversations). This is new and exciting, and while there is a part of me that will grieve for that little space where I knew most of the people who read me, I am delighted to bring anthropology to more people and keep pushing myself to write more accessibly for more people.
So, I am trying to think of next steps in terms of my writing. I still owe you all a summary of the survey I did on my readers a few weeks ago: given my day job commitments, that is the plan for what will probably be my single big post of the week.
However, I also want to continue to do two things: shorter researchblogging posts on articles I find interesting, and longer posts on specific issues around women’s health, anthropology and medicine. So if there are particular papers you want me to read, particular topics you want me to cover… say so in the comments!
*I need to double-check with the IRB about whether I have approval to advertise this on the blog. If it turns out I do, expect a post on it this week!